Predicting Tumor Response to Neoadjuvant Chemotherapy Based on Pretreatment 18 F-FDG PET/CT Parameters in Locally Advanced Oral Squamous Cell Carcinoma
Journal of Nuclear Medicine Technology · 2025
DOI: 10.2967/jnmt.125.269811 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Nuclear Medicine Technology, 2025. Verfasst von Zhengquan Hu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Fluorodeoxyglucose F18, Positron Emission Tomography Computed Tomography, Neoadjuvant Therapy, Mouth Neoplasms. Die Arbeit nennt 47 Literaturangaben.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Neoadjuvant chemotherapy (NC) is a pivotal preoperative treatment for oral squamous cell carcinoma (OSCC), but its efficacy varies among patients. This study aims to predict the efficacy of NC in patients with OSCC, facilitating precise pretreatment stratification.
Methods
We retrospectively collected pretreatment 18F-FDG parameters and clinical characteristics from 89 patients with locally advanced OSCC, including primary (n = 62) and recurrent (n = 27) OSCC. MRI was used to evaluate treatment response and calculate the depth of response (DpR), assessing the correlations between these factors and NC efficacy.
Results
In patients with primary OSCC, metabolic tumor volume (MTV) and total lesion glycolysis (TLG) were independent predictors of therapeutic response (P = 0.019 and P = 0.012, respectively). With an MTV cutoff of 11.7 cm³ and a TLG cutoff of 84.2, the areas under the receiver-operating-characteristic curve were 0.739 (P = 0.004) and 0.782 (P < 0.001), respectively. Pathologic grade, SUV, MTV, and TLG were independent predictors of DpR (P < 0.05). Pathologic grading, SUVmax normalized to lean body mass, and MTV accounted for 52.9% (coefficient of determination) of the variance in DpR without significant collinearity (variance inflation factor < 5.0). Among patients with recurrent OSCC, the SUV in NC responders was higher than that of nonresponders (P < 0.01).
Conclusion
Pretreatment 18F-FDG PET/CT parameters could predict NC response and DpR in patients with OSCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Radiology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Oral and Maxillofacial Surgery, Center of Stomatology, Central South University, Changsha, Hunan, China; hushuo2018@163.com william0732@csu.edu.cn.
- Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China; hushuo2018@163.com william0732@csu.edu.cn.
Zitieren
APA
Hu, Z., Long, T., Li, J., Li, Y., Luo, B., Wang, Y., Wu, H., Zhou, Q., Huang, J., Min, A., & Hu, S. (2025). Predicting Tumor Response to Neoadjuvant Chemotherapy Based on Pretreatment 18 F-FDG PET/CT Parameters in Locally Advanced Oral Squamous Cell Carcinoma. Journal of Nuclear Medicine Technology. https://doi.org/10.2967/jnmt.125.269811
Vancouver
Hu Z, Long T, Li J, Li Y, Luo B, Wang Y, et al. Predicting Tumor Response to Neoadjuvant Chemotherapy Based on Pretreatment 18 F-FDG PET/CT Parameters in Locally Advanced Oral Squamous Cell Carcinoma. Journal of Nuclear Medicine Technology. 2025. doi:10.2967/jnmt.125.269811
BibTeX
@article{Hu2025,
author = {Hu, Zhengquan and Long, Tingting and Li, Jian and Li, Yulai and Luo, Baihua and Wang, Ying and Wu, Haijun and Zhou, Qin and Huang, Jin and Min, Anjie and Hu, Shuo},
title = {Predicting Tumor Response to Neoadjuvant Chemotherapy Based on Pretreatment 18 F-FDG PET/CT Parameters in Locally Advanced Oral Squamous Cell Carcinoma},
journal = {Journal of Nuclear Medicine Technology},
year = {2025},
doi = {10.2967/jnmt.125.269811}
}
EUVIMED